
|Articles|February 25, 2009
Podcast- End of the world as we know it?
Advertisement
REMS: Is it the end of the world as we know it?
Risk Evaluation and Mitigation Strategies: For manufacturers, do REMS represent a tremendous potential for confusion or an opportunity for growth? Perhaps both. Manufacturers who implement effective programs can enhance patient access to medications, further ensure appropriate utilization and potentially improve patient outcomes. Manufacturers whose execution falls short stand to lose market share or even risk increased regulatory scrutiny.
Add this Podcast feed to your media player
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
2
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
3
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
4
A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims
5




